Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,732,162
  • Shares Outstanding, K 145,719
  • Annual Sales, $ 9,836 M
  • Annual Income, $ 1,161 M
  • EBIT $ 2,539 M
  • EBITDA $ 3,066 M
  • 60-Month Beta -0.06
  • Price/Sales 2.30
  • Price/Cash Flow 8.57
  • Price/Book 1.41

Options Overview Details

View History
  • Implied Volatility 30.68% ( +1.11%)
  • Historical Volatility 22.22%
  • IV Percentile 58%
  • IV Rank 35.44%
  • IV High 47.65% on 07/25/24
  • IV Low 21.36% on 09/10/24
  • Put/Call Vol Ratio 1.55
  • Today's Volume 3,813
  • Volume Avg (30-Day) 4,616
  • Put/Call OI Ratio 0.61
  • Today's Open Interest 58,925
  • Open Int (30-Day) 54,592

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 3.46
  • Number of Estimates 25
  • High Estimate 3.99
  • Low Estimate 3.26
  • Prior Year 2.95
  • Growth Rate Est. (year over year) +17.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
153.62 +1.55%
on 11/20/24
190.40 -18.07%
on 10/21/24
-34.16 (-17.96%)
since 10/18/24
3-Month
153.62 +1.55%
on 11/20/24
207.59 -24.85%
on 08/21/24
-49.49 (-24.08%)
since 08/20/24
52-Week
153.62 +1.55%
on 11/20/24
268.30 -41.86%
on 01/03/24
-74.11 (-32.21%)
since 11/20/23

Most Recent Stories

More News
UCB and Biogen Announce Positive Phase 3 Results for Dapirolizumab Pegol in Treating Moderate-to-Severe Systemic Lupus Erythematosus

Dapirolizumab pegol demonstrated significant clinical improvements in systemic lupus erythematosus, advancing treatment options for affected patients.Quiver AI SummaryDapirolizumab pegol (DZP), an investigational...

BIIB : 156.00 (+0.37%)
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

BIIB : 156.00 (+0.37%)
Stocks Settle Mostly Higher on Tech Stock Strength and Lower Bond Yields

The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.13%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.71%. Stocks on Monday...

NVDA : 145.89 (-0.76%)
HSIC : 73.73 (-1.48%)
$SPX : 5,917.11 (unch)
SMCI : 25.80 (-8.74%)
FOUR : 101.90 (-0.15%)
NKE : 73.36 (-0.74%)
OKTA : 73.69 (-1.10%)
$IUXX : 20,667.10 (-0.08%)
IQV : 194.38 (+1.59%)
QQQ : 503.17 (-0.06%)
ZNZ24 : 109-235 (+0.04%)
TSLA : 342.03 (-1.15%)
Stocks Mostly Higher on Positive Corporate News

The S&P 500 Index ($SPX ) (SPY ) today is up +0.43%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.01%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.91%. Stocks today are mostly higher...

NVDA : 145.89 (-0.76%)
$SPX : 5,917.11 (unch)
SMCI : 25.80 (-8.74%)
FOUR : 101.90 (-0.15%)
NKE : 73.36 (-0.74%)
$IUXX : 20,667.10 (-0.08%)
IQV : 194.38 (+1.59%)
QQQ : 503.17 (-0.06%)
ZNZ24 : 109-235 (+0.04%)
TSLA : 342.03 (-1.15%)
NGNE : 15.33 (-11.03%)
NEM : 42.99 (-0.44%)
Eisai and Biogen Receive Positive CHMP Opinion for Lecanemab to Treat Early Alzheimer’s Disease in Europe

Eisai and Biogen announced CHMP's positive opinion for lecanemab to treat early Alzheimer's disease in select patient groups.Quiver AI SummaryEisai Co., Ltd. and Biogen Inc. announced that the European...

BIIB : 156.00 (+0.37%)
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

BIIB : 156.00 (+0.37%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Alzheimer’s Drug Market Faces Urgent Need for Innovative Therapies Beyond Big Pharma These Small-Cap Biotech Stocks Lead the Charge with Disruptive Approaches to Treating Alzheimer’s Alzheimer’s...

ANVS : 6.54 (-2.10%)
LLY : 753.41 (+3.25%)
INMB : 4.56 (-3.18%)
XBI : 94.01 (+0.90%)
BIIB : 156.00 (+0.37%)
SAVA : 26.05 (-6.96%)
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?

Key TakeawaysLLY has declined 10.6% this month after disappointing third-quarter results.The drug maker has seen strong success in recent years, with several new drugs in the pipeline.Register now to see...

NVO : 105.27 (+2.57%)
LLY : 753.41 (+3.25%)
AMGN : 287.87 (+2.83%)
BIIB : 156.00 (+0.37%)
Big Pharma’s $13.7B Alzheimer’s Drug Market Has a Progress Problem: Here Are Three Small-Cap Biotech Stocks That Could Disrupt the Market

Small biotech firms like Cassava Sciences, INmune Bio, and Annovis Bio are developing innovative Alzheimer’s treatments, disrupting big pharma’s dominance in the $13.7B market. For those targeting...

ANVS : 6.54 (-2.10%)
LLY : 753.41 (+3.25%)
INMB : 4.56 (-3.18%)
XBI : 94.01 (+0.90%)
BIIB : 156.00 (+0.37%)
SAVA : 26.05 (-6.96%)
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

BIIB : 156.00 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement...

See More

Key Turning Points

3rd Resistance Point 159.47
2nd Resistance Point 157.83
1st Resistance Point 156.91
Last Price 156.00
1st Support Level 154.35
2nd Support Level 152.71
3rd Support Level 151.79

See More

52-Week High 268.30
Fibonacci 61.8% 224.49
Fibonacci 50% 210.96
Fibonacci 38.2% 197.43
Last Price 156.00
52-Week Low 153.62

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar